

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

LOX-IMVI

RRID:CVCL_1381

Type: Cell Line

Proper Citation

RRID:CVCL_1381

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1381

Proper Citation: RRID:CVCL_1381

Description: Cell line LOX-IMVI is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Amelanotic melanoma

Defining Citation: [PMID:2041050](#), [PMID:3335022](#), [PMID:3346110](#), [PMID:7718330](#), [PMID:7999427](#), [PMID:8631022](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12068308](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:19727395](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Characteristics: Established from a subcutaneous xenograft in nude mice., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LOX-IMVI

Synonyms: LOX/IMVI, LOX IMVI, LOXIM-VI, LOXIMVI, LOX

Cross References: BTO:BTO_0004151, CLO:CLO_0037130, EFO:EFO_0006284, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03470824, BioSample:SAMN10988372, cancercellines:CVCL_1381, Cell_Model_Passport:SIDM00149, ChEMBL-Cells:ChEMBL3307535, ChEMBL-Targets:ChEMBL614096, Cosmic:687446, Cosmic:875883, Cosmic:897466, Cosmic:905974, Cosmic:922393, Cosmic:974255, Cosmic:1044264, Cosmic:1092610, Cosmic:1175868, Cosmic:1238117, Cosmic:1303039, Cosmic:1305363, Cosmic:1312346, Cosmic:1436046, Cosmic:1477412, Cosmic:1669121, Cosmic:1998452, Cosmic:2060808, Cosmic:2651879, Cosmic-CLP:905974, DepMap:ACH-000750, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905974, GEO:GSM2170, GEO:GSM50200, GEO:GSM50262, GEO:GSM206518, GEO:GSM274687, GEO:GSM743463, GEO:GSM750808, GEO:GSM799351, GEO:GSM799414, GEO:GSM846362, GEO:GSM887275, GEO:GSM888350, GEO:GSM1153421, GEO:GSM1178309, GEO:GSM1178310, GEO:GSM1181291, GEO:GSM1181335, GEO:GSM1670056, GEO:GSM2124660, IARC_TP53:21077, LiGeA:CCLE_361, LINCS_HMS:50988, LINCS_LDP:LCL-1276, Millipore:SCC201, NCI-DTP:LOX IMVI, PharmacDB:LOXIMVI_857_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1381, PubChem_Cell_line:CVCL_1381, SKY/M-FISH/CGH:2812, Wikidata:Q54902908

ID: CVCL_1381

Record Creation Time: 20220427T220733+0000

Record Last Update: 20260913T004751+0000

Ratings and Alerts

No rating or validation information has been found for LOX-IMVI.

No alerts have been found for LOX-IMVI.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Rasbach E, et al. (2025) Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. Molecular cancer, 24(1), 310.

Degefu YN, et al. (2025) Cell state plasticity emerging from co-regulated, competitive, and configurable interactions within the AP-1 network. bioRxiv : the preprint server for biology.

Moore GL, et al. (2025) A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies. *Molecular cancer therapeutics*, 24(3), 331.

Ito J, et al. (2024) PRDX6 dictates ferroptosis sensitivity by directing cellular selenium utilization. *Molecular cell*, 84(23), 4629.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Hofman DA, et al. (2024) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *Molecular cell*, 84(2), 261.

Hlavaty SI, et al. (2024) ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. *Cell reports*, 43(12), 114988.

Hofman DA, et al. (2023) Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. *bioRxiv : the preprint server for biology*.

Comandante-Lou N, et al. (2022) AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells. *Cell reports*, 40(5), 111147.

Carotenuto P, et al. (2022) Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. *Cell reports*, 41(6), 111601.

Carcamo S, et al. (2022) Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. *Cell reports*, 39(1), 110637.

Mo X, et al. (2022) Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. *Cell*, 185(11), 1974.

Drosopoulos WC, et al. (2020) Dynamic Assembly and Disassembly of the Human DNA Polymerase γ Holoenzyme on the Genome In Vivo. *Cell reports*, 30(5), 1329.

Orgaz JL, et al. (2020) Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. *Cancer cell*, 37(1), 85.

Drosopoulos WC, et al. (2020) TRF2 Mediates Replication Initiation within Human Telomeres to Prevent Telomere Dysfunction. *Cell reports*, 33(6), 108379.

Lee JS, et al. (2018) Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. *Cell*, 174(6), 1559.

Wallstabe L, et al. (2018) CAR T cells targeting α v β 3 integrin are effective against advanced cancer in preclinical models. *Advances in cell and gene therapy*, 1(2).

Berger S, et al. (2016) Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. *eLife*, 5.